ViaCyte Receives More Funding for Diabetes Stem Cell TherapyFebruary 13, 2013 - (ViaCyte) - "JDRF, a global organization focused on type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM) agreed to provide additional funding for the development of a novel stem cell therapy by ViaCyte. JDRF and CIRM will each contribute $3 million to further advance the project." Read Full Press Release
